Premium
P2‐412: Mild cognitive impairment (MCI): Should it be treated or not?
Author(s) -
Spiru Luiza
Publication year - 2008
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2008.05.1491
Subject(s) - psychological intervention , pathological , cognition , intervention (counseling) , presentation (obstetrics) , psychology , cognitive impairment , cognitive psychology , aside , clinical psychology , medicine , psychiatry , pathology , art , literature , radiology
(0.73%) patient. Noticeable cognitive deterioration was reported by caregivers in 12 (8.8%) patients during the first month of treatment. Conclusions: Next-day crossover from galantamine ER (Razadyne ER) to rivastigmine patch (Exelon Patch) was well tolerated. Cognitive deterioration was reported by caregivers in 8.8% of patients whose treatment were switched from galantamine ER to rivastigmine patch 4.6mg/day.